Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Table 2

Overall response, AFP response, and failure pattern after treatment.

	IMRT + sorafenib (n = 36)	IMRT (n = 46)	value
	n (%)	n (%)
Overall response			0.120
CR	0 (0.0)	1 (2.2)
PR	22 (61.1)	20 (43.5)
SD	10 (27.8)	13 (28.3)
PD	4 (11.1)	12 (26.0)
AFP response			0.003
≥20%	22 (61.1)	13 (28.3)
<20%	14 (38.9)	33 (71.7)
Failure pattern
In-field recurrence	7 (19.4)	16 (34.8)	0.125
Out-field recurrence	14 (38.9)	12 (26.1)	0.216
Distant metastasis	6 (16.7)	8 (17.4)	0.931

CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.